Structural and analytical reference
Compare three lipidated research peptides by receptor classification, backbone length, chemical identity and analytical documentation.
Semaglutide is classified as a GLP-1 receptor agonist, tirzepatide as a GIP/GLP-1 receptor co-agonist, and retatrutide as a GIP/GLP-1/glucagon receptor agonist. These are different molecular designs, not interchangeable names.
The structural comparison
| Attribute | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Published receptor class | GLP-1 | GIP and GLP-1 | GIP, GLP-1 and glucagon |
| Peptide backbone | 31 residues | 39 residues | 39 residues |
| Architecture | Lipidated GLP-1 analogue | Lipidated, GIP-based analogue | Lipidated peptide described as LY3437943 |
| Identity distinction | Specific substitutions and side-chain conjugate | Different sequence and side-chain conjugate | Different sequence despite matching tirzepatide backbone length |
Backbone length counts residues in the principal peptide chain. It does not count every chemical group in a linker or lipid attachment. The table describes published molecular identities and makes no inference about the composition of a particular supplier lot.
Why receptor count is not a quality ranking
A receptor label summarizes an experimentally characterized interaction class. It does not establish equal activity at each receptor, assay equivalence, or a ranking of research-material quality. A laboratory comparison must name the receptor system, endpoint and molecular identity before interpreting a result.
Two 39-residue molecules can differ at multiple positions and in their side-chain chemistry. Chain length alone cannot establish identity. A three-receptor designation also describes one designed molecule; it is not a statement that three separate peptides have been mixed in a vial.
What to match on an analytical record
- The exact sequence, residue stereochemistry and nonstandard residues.
- The location and composition of the side-chain conjugate, plus terminal groups.
- Expected mass with its convention: average molecular mass, monoisotopic neutral mass, or a specified ion.
- Measured identity evidence and HPLC method tied to the same sample and lot.
A formula or CAS identifier helps locate a chemical record, but neither authenticates the delivered material. Compare the declared structure with the analytical assignment. Counterions, water and excipients should be addressed separately from the peptide backbone.
Format and stability
Lyophilized describes a dried presentation. It does not establish sterility, a common shelf life, or equivalent behavior after dissolution. Formulation and container-specific records remain necessary even when the molecules belong to a related peptide family.
For a stability review, keep dry-material data separate from solution data. Record the chemical form, composition and conditions supported by the supplier. A class comparison cannot supply a universal solvent or storage window.
Frequently asked questions
Are tirzepatide and retatrutide the same because both have 39 residues?
No. Matching backbone length does not mean matching sequence, conjugation or receptor classification.
Can an HPLC percentage confirm which peptide is present?
A relative chromatographic area result needs separate identity evidence. Read the chromatogram and mass assignment together.
Does this comparison establish that a research vial is equivalent to a medicine?
No. Published molecular information and regulated formulations are separate from a lot-specific research-material record.
Continue learning
Sources and scope
- Lau et al. (2015), semaglutide discovery. Primary design reference.
- Amini et al. (2025), mass-spectrometric identification of semaglutide. Primary analytical reference for the 31-residue chain.
- Coskun et al. (2018), LY3298176 discovery. Primary structural and receptor-class reference for tirzepatide.
- Coskun et al. (2022), LY3437943 discovery. Primary structural and receptor-class reference for retatrutide.
This original SRL reference uses the linked scientific and labeling records for molecular or analytical context. It does not reproduce an experimental protocol or certify a supplier batch. Prepared October 2, 2026.
